Chemical formula: C₂₅H₃₂F₃N₃O₄ Molecular mass: 495.535 g/mol PubChem compound: 5312125
Silodosin is highly selective for α1A-adrenoreceptors that are primarily located in the human prostate, bladder base, bladder neck, prostatic capsule and prostatic urethra. Blockade of these α1A-adrenoreceptors causes smooth muscle in these tissues to relax, thus decreasing bladder outlet resistance, without affecting detrusor smooth muscle contractility.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| G04CA04 | Silodosin | G Genito urinary system and sex hormones → G04 Urologicals → G04C Drugs used in benign prostatic hypertrophy → G04CA Alpha-adrenoreceptor antagonists |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| RAPAFLO Capsule | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| UROREC Hard capsule | European Medicines Agency (EU) | MPI, EU: SmPC |
Silodosin is an active ingredient of these brands:
United States (US)Australia (AU)Canada (CA)Cyprus (CY)Finland (FI)Hong Kong (HK)Japan (JP)Netherlands (NL)South Africa (ZA)Tunisia (TN)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
